Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Stopped early

Conditions studied: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma

In brief

Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. The Strata Trial uses surplus, or leftover, tumor specimens for molecular profiling and does not require additional study-specific procedures.

Key facts

Study ID

NCT03061305

Run by

Strata Oncology

People needed

58213

Starts

2016-11-01

Expected to finish

2024-06-27

Last updated by the study team

2025-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must be ≥ 18 years of age.
• Subjects must have histologically documented solid tumors (including lymphoma and multiple myeloma).
• Specific criteria for individual tumor types are as follows:
• Participants with gliomas are eligible at any stage of disease
• Participants with pancreatic carcinoma are eligible at any stage of disease
• Participants with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV.
• Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer.
• Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer.
• Must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.

Where it is running

• University of Alabama, Birmingham — Birmingham, Alabama, United States
• Kaiser Permanente - Southern California — Pasadena, California, United States
• Kaiser Permanente - Northern California — Vallejo, California, United States
• SCL Health — Broomfield, Colorado, United States
• Kaiser Permanente Colorado — Denver, Colorado, United States
• Christiana Care Health System — Newark, Delaware, United States
• SwedishAmerican — Rockford, Illinois, United States
• Baptist Health — Lexington, Kentucky, United States
• Christus Health — Lake Charles, Louisiana, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• Kaiser Permanente - Mid-Atlantic — Rockville, Maryland, United States
• Minnesota Oncology - Burnsville — Burnsville, Minnesota, United States
• Minnesota Oncology - Coon Rapids — Coon Rapids, Minnesota, United States
• Fairview Southdale Hospital — Edina, Minnesota, United States
• Minnesota Oncology - Maplewood Cancer Center — Maplewood, Minnesota, United States
• St. John's Hospital — Maplewood, Minnesota, United States
• Metro-Minnesota Community Oncology Research Consortium — Minneapolis, Minnesota, United States
• Regions Hospital — Minneapolis, Minnesota, United States
• Minnesota Oncology - Minneapolis — Minneapolis, Minnesota, United States
• North Memorial Health Care — Robbinsdale, Minnesota, United States
• Park Nicollet Health Services — Saint Louis Park, Minnesota, United States
• Minnesota Oncology - Edina — Saint Louis Park, Minnesota, United States
• Minnesota Oncology - Woodbury Clinic — Woodbury, Minnesota, United States
• North Mississippi Medical Center — Tupelo, Mississippi, United States
• University of North Carolina, Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.